Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. More Details
Flawless balance sheet with high growth potential.
Share Price & News
How has Vericel's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VCEL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: VCEL's weekly volatility (8%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: VCEL exceeded the US Biotechs industry which returned 25.4% over the past year.
Return vs Market: VCEL exceeded the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Vericel's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StVericel Corporation's (NASDAQ:VCEL) Stock Is Going Strong: Have Financials A Role To Play?
4 months ago | Simply Wall StStatutory Profit Doesn't Reflect How Good Vericel's (NASDAQ:VCEL) Earnings Are
8 months ago | Simply Wall StResults: Vericel Corporation Confounded Analyst Expectations With A Surprise Profit
Is Vericel undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: VCEL ($52.94) is trading below our estimate of fair value ($63.73)
Significantly Below Fair Value: VCEL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: VCEL is poor value based on its PE Ratio (562.6x) compared to the US Biotechs industry average (21.8x).
PE vs Market: VCEL is poor value based on its PE Ratio (562.6x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: VCEL is poor value based on its PEG Ratio (9.2x)
Price to Book Ratio
PB vs Industry: VCEL is overvalued based on its PB Ratio (17.5x) compared to the US Biotechs industry average (2.8x).
How is Vericel forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VCEL's forecast earnings growth (61.2% per year) is above the savings rate (2%).
Earnings vs Market: VCEL's earnings (61.2% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: VCEL's revenue (28.6% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: VCEL's revenue (28.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VCEL's Return on Equity is forecast to be high in 3 years time
How has Vericel performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VCEL has high quality earnings.
Growing Profit Margin: VCEL became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: VCEL has become profitable over the past 5 years, growing earnings by 40.5% per year.
Accelerating Growth: VCEL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: VCEL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (32.6%).
Return on Equity
High ROE: VCEL's Return on Equity (3.1%) is considered low.
How is Vericel's financial position?
Financial Position Analysis
Short Term Liabilities: VCEL's short term assets ($127.2M) exceed its short term liabilities ($23.2M).
Long Term Liabilities: VCEL's short term assets ($127.2M) exceed its long term liabilities ($48.0M).
Debt to Equity History and Analysis
Debt Level: VCEL is debt free.
Reducing Debt: VCEL has no debt compared to 5 years ago when its debt to equity ratio was 0.5%.
Debt Coverage: VCEL has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: VCEL has no debt, therefore coverage of interest payments is not a concern.
What is Vericel current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VCEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VCEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VCEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VCEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VCEL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nick Colangelo (57 yo)
Mr. Dominick C. Colangelo, also known as Nick, Esq., has been the Chief Executive Officer and President at Vericel Corporation. since March 1, 2013 and served as its Treasurer since May 7, 2014. He has bee...
CEO Compensation Analysis
Compensation vs Market: Nick's total compensation ($USD4.41M) is about average for companies of similar size in the US market ($USD5.32M).
Compensation vs Earnings: Nick's compensation has been consistent with company performance over the past year.
Experienced Management: VCEL's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Experienced Board: VCEL's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: VCEL insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Vericel Corporation's company bio, employee growth, exchange listings and data sources
- Name: Vericel Corporation
- Ticker: VCEL
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.454b
- Shares outstanding: 46.36m
- Website: https://vcel.com
Number of Employees
- Vericel Corporation
- 64 Sidney Street
- United States
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United Stat...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/01 22:30|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.